Navigation Links
Hiemstra Appoints Robert C. Glines as Director of Business Development
Date:3/3/2008

Team expansion to ensure highest level of quality and customer satisfaction

SAN FRANCISCO, Calif., March 3 /PRNewswire/ -- Hiemstra Product Development, an innovative, product design and development company, serving the life sciences industry, today announced the appointment of Robert C. (Bo) Glines as Director of Business Development. As the company continues to expand and broaden its capabilities, Mr. Glines ensures quality, customized programs for each client.

Mr. Glines joins Hiemstra with over 20 years of technical, marketing, and business savvy from his experiences with life science Fortune 500 companies including Johnson & Johnson, Medtronic and Boston Scientific, and start-ups, such as CardioThoracic Systems (CTSI), Microheart, Inc., and AngioSense, Inc. He was part of the original, early-stage R&D team at CTSI, where he helped invent the platform technologies and continued through the IPO (which was one of the fastest IPO's of any medical device company). Mr. Glines co-founded Microheart, a needle-based drug delivery company, and founded AngioSense, a drug/device biotechnology venture in the field of gene therapy, where he raised an initial $4 million of financing. He has developed innovative medical technologies and worked with companies from inception to mature enterprises in clinical markets such as cardiac surgery, interventional cardiology, electrophysiology, gene therapy and drug delivery. Mr. Glines has 16 issued patents and numerous patent applications pending, and has coauthored several scientific and clinical publications.

"Today in the Med Tech sector, resource expansion is 'red hot!'," claims Glines. "Now with a 13485-certified clean room, our clients can leverage our infrastructure, experienced resources and CER to accelerate development of their products, from napkin sketch to commercialization." With his intimate knowledge of the medical technology sector, Mr. Glines brings a unique, focused vision as the company expan
'/>"/>

SOURCE Hiemstra Product Development
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... -- STOCKHOLM, August 27, 2010 ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... Massachusetts, August 26, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
... CARY, N.C., Aug. 26 SciQuest, Inc ... procurement and supplier enablement solutions, ... list of the fastest-growing, private companies in America. ... in 2007. (Logo: http://photos.prnewswire.com/prnh/20100624/DA25925LOGO ) ...
Cached Biology Technology:Athera Signs Distribution Agreement in Scandinavia 2Athera Signs Distribution Agreement in Scandinavia 3Athera Signs Distribution Agreement in Scandinavia 4Athera Signs Distribution Agreement in Scandinavia 5Athera Signs Distribution Agreement in Scandinavia 6Athera Signs Distribution Agreement in Scandinavia 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 2Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 3Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 4Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 5Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 6Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 8Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 9SciQuest Makes the Inc. 500|5000 List of Fastest-Growing Companies for Fourth Consecutive Year 2
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... have sexes, just so-called mating types. A new study ... there are great similarities between the parts of DNA that ... of DNA that determine mating types in certain fungi. ... of the evolutionary development of sex chromosomes. In the ...
... National Lung Cancer Partnership, in partnership with the ... their third annual research grant competition. The ... in basic lung cancer biology, risk assessment, prevention, detection, ... Genentech and our very generous donors, were able to ...
... leading causes of blindnessage-related macular degeneration and diabetic retinopathycan ... a protein found in blood vessel cells, researchers at ... other institutions have announced in a new study. ... when the protein, Robo4, was activated in mice models ...
Cached Biology News:Fungi can tell us about the origin of sex chromosomes 2National Lung Cancer Partnership and LUNGevity Foundation 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 3
... to significantly increase the shelf life of ... increased at room temperature storage conditions in ... is subjected to 0.45 micron filtration, and ... formulation insures consistently high levels of activity ...
... been developed to significantly increase the shelf ... Stability is increased at room temperature storage ... This product is subjected to 0.2 micron ... This formulation insures consistently high levels ...
These 25x25 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 102...
... Cell Cultures (ECACC) has been offering training ... government institutes for over seven years. We ... introduce candidates to cell culture and a ... specialist areas such as planning and management ...
Biology Products: